Depression: all studies (page 224) - The Consciousness Library

Effects of Mindfulness-Based Stress Reduction (MBSR) Program on Anxiety and Depression and HRQoL among Cancer Patients in Malaysia.

Environment-Behaviour Proceedings Journal December 12, 2021 Che Noriah Binti Othman, Syed Azhar Syed Sulaiman, Maryam Farooqui et al.

Anxiety and depression are common among cancer patients and impact health-related quality of life. MBSR has long been used to treat psychological illnesses in various therapeutic settings worldwide. However, there is no solid evidence of MBSR effects among cancer patients in Malaysia. This cross-sectional study intervened in the five weeks of MBSR on cancer patients in Penang. Results found...

DOI: 10.21834/ebpj.v6i18.3072

Racemic Ketamine as an Alternative to Electroconvulsive Therapy for Unipolar Depression: A Randomized, Open-Label, Non-Inferiority Trial (KetECT)

The International Journal of Neuropsychopharmacology December 4, 2021 Joakim Ekstrand, Christian Fattah, Marcus Persson et al. 112 citations

Abstract Background Ketamine has emerged as a fast-acting and powerful antidepressant, but no head to head trial has been performed, Here, ketamine is compared with electroconvulsive therapy (ECT), the most effective therapy for depression. Methods Hospitalized patients with unipolar depression were randomized (1:1) to thrice-weekly racemic ketamine (0.5 mg/kg) infusions or ECT in a parallel,...

DOI: 10.1093/ijnp/pyab088 Full text

Case Report: Repeated Series of Ketamine Infusions in Patients With Treatment-Resistant Depression: Presentation of Five Cases

Frontiers in Psychiatry December 2, 2021 Maria Gałuszko‐węgielnik, Adam Włodarczyk, Wiesław Jerzy Cubała et al. 5 citations

Purpose: Approximately 30% of patients with major depressive disorder (MDD) are treatment resistant. There is an unquestionable need for new treatment strategies. Subanesthetic doses of intravenous (IV) ketamine have a rapid antidepressant effect in treatment-resistant depression (TRD). This paper describes the efficacy of repeated series of intravenous ketamine infusions as an add-on treatment...

DOI: 10.3389/fpsyt.2021.705190 Ketamine Treatment-resistant depression Major depressive disorder Depression economics +5

Ketamine vs Midazolam: Mood Improvement Reduces Suicidal Ideation in Depression

Journal of Affective Disorders December 1, 2021 Annabella Hochschild, John G Keilp, Sean P Madden et al.

Objective: Studies demonstrate rapid antidepressant and anti-suicidal ideation effects of subanesthetic ketamine. The specific subcomponents of depression that are most closely tied to reduction of suicidal ideation with ketamine treatment are less explored. Methods: Exploratory, post hoc analysis of data from a randomized clinical trial of ketamine vs midazolam in patients with major...

DOI: 10.1016/j.jad.2021.12.055 Full text

Comparative effectiveness of repeated ketamine infusions in treating anhedonia in bipolar and unipolar depression.

Journal of Affective Disorders December 1, 2021 Wei Zheng, Lingna Gu, Chen-Hui Sun et al.

OBJECTIVES Anhedonia is a common, persistent, and disabling phenomenon in patients with major depressive disorder (MDD) and bipolar depression (BD). This study was conducted to investigate the comparative effectiveness of repeated ketamine infusions in treating anhedonia in Chinese individuals suffering from MDD and BD. METHODS Ninety-seven individuals suffering from MDD (n=77) or BD (n=20)...

DOI: 10.1016/j.jad.2021.12.105

P.0729 Highlights of psychedelic history and current research on psilocybin application for treatment of depression – a comprehensive literature review

European Neuropsychopharmacology December 1, 2021 S. Penedos, C. Ramos, M. Miguel et al. 1 citation

Introduction: Psychedelics have seen various labels: mystical sacrament aids, potential interrogation tools for the Cold War, agents for social change in the Hippie counter movement, a panacea for various mental disorders, and a tool to “hack” of the psyche. This has led to their reputation as both societal threat and a psychopharmacological breakthrough. After the loss of data on over 1000...

DOI: 10.1016/j.euroneuro.2021.10.797

Psilocybin-assisted psychotherapy for depression: Emerging research on a psychedelic compound with a rich history.

Journal of Neurological Sciences December 1, 2021 Craig S Pearson, J. Siegel, J. Gold 30 citations

There is a serious need for novel therapies that treat individuals with depression, including major depressive disorder (MDD) and treatment-resistant depression (TRD). An emerging body of research has demonstrated that psychedelic drugs such as psilocybin, combined with supportive psychotherapy, exert rapid and sustained antidepressant effects. The use of psychedelics is not new: they have a...

DOI: 10.1016/j.jns.2021.120096

Psilocybin-assisted therapy for the treatment of resistant major depressive disorder (PsiDeR): protocol for a randomised, placebo-controlled feasibility trial

BMJ Open December 1, 2021 James Rucker, Hassan Jafari, Tim Mantingh et al. 23 citations

Introduction Psilocybin-assisted therapy may be a new treatment for major depressive disorder (MDD), with encouraging data from pilot trials. In this trial (short name: PsiDeR) we aimed to test the feasibility of a parallel-group, randomised, placebo-controlled design. The primary outcomes in this trial are measures of feasibility: recruitment rates, dropout rates and the variance of the...

DOI: 10.1136/bmjopen-2021-056091 Full text Psilocybin Major depressive disorder Treatment-resistant depression Placebo +10

Identification of an Optimal Dose of Intravenous Ketamine for Late-Life Treatment-Resistant Depression: A Bayesian Adaptive Randomization Trial

Neuropsychopharmacology November 27, 2021 Marijn Lijffijt, Nicholas Murphy, Sidra Iqbal et al.

Evidence supporting specific therapies for late-life treatment-resistant depression (LL-TRD) is necessary. This study used Bayesian adaptive randomization to determine the optimal dose for the probability of treatment response (≥50% improvement from baseline on the Montgomery-Åsberg Depression Rating Scale) 7 days after a 40 min intravenous (IV) infusion of ketamine 0.1 mg/kg (KET 0.1), 0.25...

DOI: 10.1038/s41386-021-01242-9 Full text

Lithium augmentation of ketamine increases insulin signaling and antidepressant-like active stress coping in a rodent model of treatment-resistant depression

Translational Psychiatry November 25, 2021 Blair J. Price, Brooke Morath, Mayo Clinic et al.

Lithium, a mood stabilizer and common adjunctive treatment for refractory depression, shares overlapping mechanisms of action with ketamine and enhances the duration of ketamine’s antidepressant actions in rodent models at sub-therapeutic doses. Yet, in a recent clinical trial, lithium co-treatment with ketamine failed to improve antidepressant outcomes in subjects previously shown to respond...

DOI: 10.1038/s41398-021-01716-w Full text

Research